Literature DB >> 17665313

Protection of mammography screening against death from breast cancer in women aged 40-64 years.

Sandra A Norman1, A Russell Localio, Anita L Weber, Ralph J Coates, Lan Zhou, Leslie Bernstein, Kathleen E Malone, Polly A Marchbanks, Linda K Weiss, Nancy C Lee, Marion R Nadel.   

Abstract

OBJECTIVE: This study assessed the efficacy of community-based screening mammography in protecting against breast cancer death, asking whether age differences in efficacy persisted in the 1990s.
METHODS: In a case-control study with follow-up, odds ratios (OR) were used to estimate the relative mortality rates from invasive breast cancer among women with at least one screening mammogram in the two years prior to a baseline reference date compared to non-screened women, adjusting for potential confounding. The multicenter population-based study included 553 black and white women diagnosed during 1994-1998 who died in the following five years, and 4016 controls without breast cancer.
RESULTS: Efficacy for reducing the rate of breast cancer death within five years after diagnosis was greater at ages 50-64 years (OR = 0.47, 95% confidence interval (CI) 0.35-0.63) than at ages 40-49 (OR = 0.89, 95% CI 0.65-1.23), and greater among postmenopausal (OR = 0.45, 95% CI 0.33-0.62) than premenopausal women (OR = 0.74, 95% CI 0.53-1.04). Estimates of efficacy were conservative, as shown by sensitivity analyses addressing whether cancer was discovered by a screening mammogram, age at which screening was received, the length of the screening observation window, and years of follow-up after diagnosis.
CONCLUSIONS: Despite the persistence of age differences in efficacy of mammography screening, with greater observed benefit for women aged 50-64 years, these findings support current screening recommendations for women 40-64 years old.

Entities:  

Mesh:

Year:  2007        PMID: 17665313     DOI: 10.1007/s10552-007-9006-8

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  7 in total

1.  Hormone therapy and fatal breast cancer.

Authors:  Sandra A Norman; Anita L Weber; A Russell Localio; Polly A Marchbanks; Giske Ursin; Brian L Strom; Linda K Weiss; Ronald T Burkman; Leslie Bernstein; Dennis M Deapen; Suzanne G Folger; Michael S Simon; Marion R Nadel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-05       Impact factor: 2.890

Review 2.  The benefits and harms of breast cancer screening: an independent review.

Authors:  M G Marmot; D G Altman; D A Cameron; J A Dewar; S G Thompson; M Wilcox
Journal:  Br J Cancer       Date:  2013-06-06       Impact factor: 7.640

3.  Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.

Authors:  Tasha R Smith; Wen Liu-Mares; Beth O Van Emburgh; Edward A Levine; Glenn O Allen; Jeff W Hill; Isildinha M Reis; Laura A Kresty; Mark D Pegram; Mark S Miller; Jennifer J Hu
Journal:  Carcinogenesis       Date:  2011-06-23       Impact factor: 4.944

4.  Geographic disparities in mammography capacity in the South: a longitudinal assessment of supply and demand.

Authors:  Jan M Eberth; Karl Eschbach; Jeffrey S Morris; Hoang T Nguyen; Md Monir Hossain; Linda S Elting
Journal:  Health Serv Res       Date:  2013-07-05       Impact factor: 3.402

5.  Why Was the US Preventive Services Task Force's 2009 Breast Cancer Screening Recommendation So Objectionable? A Historical Analysis.

Authors:  Barron H Lerner; Graham Curtiss-Rowlands
Journal:  Milbank Q       Date:  2022-09-23       Impact factor: 6.237

Review 6.  Promoter methylation and the detection of breast cancer.

Authors:  Jennifer Brooks; Paul Cairns; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2009-11       Impact factor: 2.506

7.  Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.

Authors:  Jeanne S Mandelblatt; Kathleen A Cronin; Stephanie Bailey; Donald A Berry; Harry J de Koning; Gerrit Draisma; Hui Huang; Sandra J Lee; Mark Munsell; Sylvia K Plevritis; Peter Ravdin; Clyde B Schechter; Bronislava Sigal; Michael A Stoto; Natasha K Stout; Nicolien T van Ravesteyn; John Venier; Marvin Zelen; Eric J Feuer
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.